Armata Pharmaceuticals' core business segment revolves around the development of targeted bacteriophage therapeutics to combat antibiotic-resistant infections. This includes research and development of novel phage-based therapies, conducting preclinical studies and clinical trials, and seeking regulatory approvals for their product candidates. The company's pipeline features candidates like AP-SA02 for Staphylococcus aureus bacteremia, AP-PA02 for Pseudomonas aeruginosa infections, and AP-PA03 for pneumonia. Their approach leverages pathogen-specific bacteriophages to selectively target and eliminate harmful bacteria, offering a potential solution to the growing problem of antimicrobial resistance. This segment aims to improve patient outcomes by providing effective alternatives to traditional antibiotics, particularly in cases where resistance has rendered conventional treatments ineffective. Future opportunities include expanding the pipeline with new phage therapies, securing partnerships for commercialization, and addressing unmet needs in the treatment of various infectious diseases.

This segment focuses on the proprietary bacteriophage-based technology that forms the foundation of Armata's therapeutic development. It encompasses the discovery, engineering, and optimization of bacteriophages for targeted bacterial killing. Research and development efforts are directed towards enhancing phage specificity, potency, and delivery methods. The technology platform also involves intellectual property management, including patent filings and protection of proprietary phage libraries. This segment supports the development of a diverse pipeline of phage-based therapies and enables strategic partnerships with other pharmaceutical companies. The platform's capabilities extend to synthetic bacteriophage development, as demonstrated by the collaboration with Merck & Co. Future opportunities include expanding the platform's capabilities through advanced technologies like synthetic biology and bioinformatics, and leveraging the platform to address a wider range of infectious diseases.